Feb. 24 at 5:35 PM
$IBRX $XBI $MRNA $IWM $QQQ forgot to mention that since the mid-February regulatory milestones, covering analysts have reiterated high expectations for the stock:
Jason Kolbert(love this guy, smartest one of the bunch)
(D. Boral Capital): On February 17, 2026, Kolbert reiterated a Buy rating and a
$24.00 price target, citing the company's rapid global expansion and the de-risked path for the U.S. papillary indication.
Andres Y. Maldonado
(H.C. Wainwright): maintains strong Buy rating raising its price target to
$15 with a
$10.00 price target, this hike followed the announcement of
$113 million in 2025 net product revenue (a 700% year-over-year increase) and the Accord Healthcare partnership for EU distribution.
Others, including those at Truist(small stake), have identified IBRX as a potential future candidate for the S&P 500 or the S&P MidCap 400 if its current growth trajectory and path to profitability continue through 2026.
More will be raising as co becomes de-risked !
